Sponsored by
I am very excited about this treatment. This is the first trial to ever report extended survival in both newly diagnosed and recurrent Glioblastoma. For newly diagnosed Glioblastoma, 5 year survival more than doubled from 5.7% to 13%. And for recurrent Glioblastoma, survival at 20 months and 30 months also doubled, from 9.6% to 15.7% at 24 months and from 5.1% to 11.1% at 30 months. This is all with a few simple injections which had no side effects.